The use of primaquine in malaria infected patients with red cell glucose-6-phosphate dehydrogenase (G6PD) deficiency in Myanmar.
Southeast Asian J Trop Med Public Health
; 1994 Dec; 25(4): 710-3
Article
in En
| IMSEAR
| ID: sea-31323
ABSTRACT
32 subjects with Plasmodium falciparum gametocytes, and 31 cases with Plasmodium vivax infection from two military hospitals (Lashio, Mandalay) were treated with quinine 600 mg three times a day for 7 days followed by primaquine 45 mg single dose for gametocytes and 45 mg weekly x 8 weeks for vivax malaria. Although screening of red cell glucose-6-phosphate dehydrogenase (G6PD) was done prior to primaquine treatment, G6PD deficient subjects were not excluded from the trial. 20 patients hemizygous for mild G6PD deficiency (GdB- variant), 2 patients hemizygous for severe deficiency (Gd-Myanmar variant) completed the trial. No case of acute hemolysis was observed in all 22 patients with two genotypes of red cell G6PD deficiency status. Therefore, a single dose of primaquine 45 mg and/or weekly for 8 weeks is adequate for the treatment of patients with P. falciparum gametocytes and/or P. vivax malaria ignoring these red cell G6PD enzyme deficient variants in Myanmar.
Full text:
1
Index:
IMSEAR
Main subject:
Primaquine
/
Humans
/
Methemoglobin
/
Drug Administration Schedule
/
Malaria, Vivax
/
Malaria, Falciparum
/
Myanmar
/
Developing Countries
/
Dose-Response Relationship, Drug
/
Erythrocytes
Country/Region as subject:
Asia
Language:
En
Journal:
Southeast Asian J Trop Med Public Health
Year:
1994
Type:
Article